Display options
Cite
Tomizawa M, Shinozaki F, Motoyoshi Y, et al. Proliferation and motility of hepatocellular, pancreatic and gastric cancer cells grown in a medium without glucose and arginine, but with galactose and ornithine. Oncol Lett. 2017;13(3):1276-1280doi: 10.3892/ol.2017.5568.
Tomizawa, M., Shinozaki, F., Motoyoshi, Y., Sugiyama, T., Yamamoto, S., & Ishige, N. (2017). Proliferation and motility of hepatocellular, pancreatic and gastric cancer cells grown in a medium without glucose and arginine, but with galactose and ornithine. Oncology letters, 13(3), 1276-1280. https://doi.org/10.3892/ol.2017.5568
Tomizawa, Minoru, et al. "Proliferation and motility of hepatocellular, pancreatic and gastric cancer cells grown in a medium without glucose and arginine, but with galactose and ornithine." Oncology letters vol. 13,3 (2017): 1276-1280. doi: https://doi.org/10.3892/ol.2017.5568
Tomizawa M, Shinozaki F, Motoyoshi Y, Sugiyama T, Yamamoto S, Ishige N. Proliferation and motility of hepatocellular, pancreatic and gastric cancer cells grown in a medium without glucose and arginine, but with galactose and ornithine. Oncol Lett. 2017 Mar;13(3):1276-1280. doi: 10.3892/ol.2017.5568. Epub 2017 Jan 04. PMID: 28454246; PMCID: PMC5403308.
Copy Download .nbib Format: NLM
Share it on

Oncol Lett. 2017 Mar;13(3):1276-1280. doi: 10.3892/ol.2017.5568. Epub 2017 Jan 04.

Proliferation and motility of hepatocellular, pancreatic and gastric cancer cells grown in a medium without glucose and arginine, but with galactose and ornithine.

Oncology letters

Minoru Tomizawa, Fuminobu Shinozaki, Yasufumi Motoyoshi, Takao Sugiyama, Shigenori Yamamoto, Naoki Ishige

Affiliations

  1. Department of Gastroenterology, National Hospital Organization, Shimoshizu Hospital, Yotsukaido, Chiba 284-0003, Japan.
  2. Department of Radiology, National Hospital Organization, Shimoshizu Hospital, Yotsukaido, Chiba 284-0003, Japan.
  3. Department of Neurology, National Hospital Organization, Shimoshizu Hospital, Yotsukaido, Chiba 284-0003, Japan.
  4. Department of Rheumatology, National Hospital Organization, Shimoshizu Hospital, Yotsukaido, Chiba 284-0003, Japan.
  5. Department of Pediatrics, National Hospital Organization, Shimoshizu Hospital, Yotsukaido, Chiba 284-0003, Japan.
  6. Department of Neurosurgery, National Hospital Organization, Shimoshizu Hospital, Yotsukaido, Chiba 284-0003, Japan.

PMID: 28454246 PMCID: PMC5403308 DOI: 10.3892/ol.2017.5568

Abstract

Human primary hepatocytes are able to survive in a medium without glucose and arginine, but supplemented with galactose and ornithine (hepatocyte selection medium; HSM). To address the possibility of the application of HSM in cancer therapy, hepatocellular carcinoma cells, pancreatic cancer cells and gastric cancer cells were cultured in HSM. Cell proliferation was analyzed using an MTS assay. Morphological changes were analyzed using hematoxylin and eosin staining. Apoptosis was analyzed using a TUNEL assay and cell motility was assessed with a scratch assay. Cell proliferation was significantly suppressed in cell lines grown in HSM (P<0.01 in all the cell lines). Hematoxylin and eosin staining revealed pyknotic nuclei, suggesting that these cells had undergone apoptosis. The number of TUNEL-positive cells was significantly increased in HSM. In the scratch assay, the distance between the growing edge and the scratched edge was significantly lower (P<0.01 in all the cell lines) in cells cultured in HSM, compared with those grown in Dulbecco's modified Eagle's medium or RPMI-1640. Therefore, the proliferation and motility of hepatocellular carcinoma cells, pancreatic cancer cells and gastric cancer cells was suppressed, and these cells subsequently underwent apoptosis in a medium without glucose and arginine, but containing galactose and ornithine.

Keywords: arginine; galactokinase; galactose; glucose; ornithine; urea cycle

References

  1. Glia. 2012 Nov;60(11):1747-60 - PubMed
  2. Neurol Res. 1994 Dec;16(6):460-4 - PubMed
  3. J Cell Biol. 1972 Mar;52(3):559-68 - PubMed
  4. Curr Opin Clin Nutr Metab Care. 2015 Jan;18(1):78-82 - PubMed
  5. Dig Liver Dis. 2015 Jun;47(6):443-54 - PubMed
  6. Genes Cancer. 2014 May;5(5-6):175-85 - PubMed
  7. Metabolomics. 2015 Aug;11(4):787-796 - PubMed
  8. Cancer Lett. 2015 Aug 1;364(1):1-7 - PubMed
  9. Metabolism. 2002 Jul;51(7):876-80 - PubMed
  10. World J Hepatol. 2014 Dec 27;6(12):844-50 - PubMed
  11. Biomed Res Int. 2014;2014:926729 - PubMed
  12. Liver Cancer. 2014 Mar;3(1):9-17 - PubMed
  13. Cancer Cell Int. 2014 Jul 04;14:60 - PubMed
  14. Cell Tissue Res. 2008 Jul;333(1):17-27 - PubMed
  15. Cancer. 2014 Mar 15;120(6):774-80 - PubMed
  16. Cell Physiol Biochem. 2000;10(1-2):37-55 - PubMed
  17. Brain Res. 2015 Jul 10;1613:110-9 - PubMed
  18. Biochem Biophys Res Commun. 2005 May 27;331(1):239-46 - PubMed
  19. Cell Death Dis. 2013 Oct 10;4:e840 - PubMed
  20. Amino Acids. 2013 Nov;45(5):1221-30 - PubMed
  21. Semin Intervent Radiol. 2013 Mar;30(1):3-11 - PubMed
  22. Mol Med Rep. 2015 Jan;11(1):719-23 - PubMed
  23. Expert Opin Ther Targets. 2015;19(12):1623-35 - PubMed
  24. Contemp Oncol (Pozn). 2015;19(2):87-92 - PubMed
  25. Biochem Biophys Res Commun. 1984 Aug 16;122(3):884-91 - PubMed
  26. Liver Cancer. 2014 May;3(2):119-24 - PubMed
  27. Genome Res. 1995 Aug;5(1):53-9 - PubMed
  28. Eur J Biochem. 2002 Feb;269(3):792-7 - PubMed
  29. Cancers (Basel). 2014 Sep 29;6(4):1821-89 - PubMed
  30. J Surg Oncol. 2015 Jun;111(8):1021-7 - PubMed
  31. World J Hepatol. 2015 Feb 27;7(2):261-9 - PubMed
  32. World J Gastroenterol. 2011 May 21;17(19):2372-8 - PubMed
  33. PLoS One. 2013 Aug 14;8(8):e71897 - PubMed

Publication Types